Old Articles: <Older 8011-8020 Newer> |
|
The Motley Fool October 31, 2011 Brian Orelli |
Spectrum Looking More Investable Spectrum's problem is that it's hard to value the unknown. |
The Motley Fool October 31, 2011 Eric Bleeker |
Where Amgen Is Finding Its Growth Five years ago, Amgen collected 83% of its sales from the United States. |
The Motley Fool October 31, 2011 Brian Orelli |
When Getting Beat Down Is No Big Deal Merck is getting smacked down by Vertex Pharmaceuticals in the hepatitis C market, but it has the bulk to take a beating. |
CIO October 28, 2011 Kim S. Nash |
Challenging Times for Pfizer As drug patents expire, the pharmaceutical giant is investing in technology and emerging markets while cutting back on R&D and labor. |
The Motley Fool October 29, 2011 Frank Vinluan |
IBM's Watson Offers a Glimpse Into Health IT's Future The supercomputer will help doctors, not replace them, as one IBM official sees it. |
The Motley Fool October 28, 2011 Dawn Kawamoto |
Supplement Makers Choke With Vitamin E Tied to Prostate Cancer A study gives vitamin supplement makers and their investors a potentially bitter pill to swallow. |
The Motley Fool October 28, 2011 Brian Orelli |
Invest in Biotechs Going After Unmet Needs What a quarter it was for Vertex Pharmaceuticals: $420 million in net sales of its new hepatitis C drug. |
The Motley Fool October 27, 2011 Eric Bleeker |
Here's Where Agilent's Finding Its Growth Four years ago, Agilent produced 34% of its sales within the United States. |
The Motley Fool October 27, 2011 Brian Orelli |
DEFINE First, CONFIRM Second, See Shares Rise 60% Third Biogen CONFIRMs it has a new blockbuster drug and shares jump. |
The Motley Fool October 27, 2011 Eric Bleeker |
Here's Where Pfizer's Finding Its Growth Let's examine where Pfizer's sales and earnings come from and how its sales abroad have changed over time. |
<Older 8011-8020 Newer> Return to current articles. |